By Nana O 
A groundbreaking study led by researchers at NYU Langone Health and its Perlmutter Cancer Center has unveiled a promising new method for predicting the recurrence of stage III melanoma, a particularly aggressive form of skin cancer. The findings suggest that monitoring specific fragments of DNA, known as circulating tumor DNA (ctDNA), in a patient’s bloodstream before and during treatment could serve as a powerful tool for oncologists to identify those at highest risk of their disease returning. This research, published in the esteemed journal The Lancet Oncology, represents a significant advancement in the ongoing quest for earlier and more accurate cancer detection and management.
Early Detection: A Crucial Frontier in Melanoma Treatment
Melanoma, especially in its later stages, poses a formidable challenge to medical professionals. Stage III melanoma, characterized by the spread of tumor cells from the skin to nearby lymph nodes, requires rigorous treatment, often involving the surgical removal of these affected lymph nodes. However, even after successful surgery, the specter of recurrence looms large. Traditional surveillance methods, such as X-rays and CT scans, can sometimes be insufficient in detecting the subtle regrowth of cancer cells in their nascent stages, potentially delaying crucial interventions. This diagnostic gap has long fueled the search for more sensitive and specific biomarkers that can provide an earlier warning of disease progression.
The study’s findings indicate that approximately 80% of stage III melanoma patients who had detectable levels of ctDNA in their blood prior to initiating therapy to suppress their tumors ultimately experienced a recurrence. This alarming statistic underscores the potential of ctDNA as a predictive marker. Furthermore, the research team observed a stark difference in the speed of recurrence between patients with and without detectable ctDNA. Those with the presence of this biomarker experienced disease return more than four times faster than their counterparts who had no detectable levels. Crucially, the study also established a dose-response relationship: the higher the ctDNA levels detected, the more rapid the cancer’s resurgence.
ctDNA: A Window into the Tumor’s Presence
Circulating tumor DNA consists of small fragments of genetic material shed into the bloodstream as tumor cells break down. This innovative ctDNA method focuses on identifying the most common mutations characteristic of melanoma cells. As these cells die, their mutated DNA is released, offering a non-invasive glimpse into the tumor’s activity and presence within the body.
"Our findings suggest that circulating tumor DNA tests could help oncologists identify which melanoma patients are most likely to respond well to therapy," stated study lead author Mahrukh Syeda, MS, a research scientist in the Ronald O. Perlman Department of Dermatology at NYU Grossman School of Medicine. "In the future, such assessments may be used routinely in the clinic to help guide treatment decisions." This sentiment highlights the potential paradigm shift ctDNA testing could bring to clinical practice, moving from reactive treatment to proactive, personalized care.
A Timeline of Recurrence: Patterns in ctDNA Detection
The research team’s analysis extended beyond pre-treatment ctDNA levels, examining the biomarker’s presence at various points during therapy. Their findings revealed that nearly all patients who had detectable ctDNA levels at three, six, nine, or twelve months into their treatment experienced melanoma recurrence. This provides a crucial timeline for monitoring treatment efficacy and detecting relapse. The appearance of ctDNA after an initial negative test, or a sustained presence throughout treatment, could serve as an early indicator that the disease is not being fully controlled or is beginning to worsen.
This longitudinal monitoring capability is particularly valuable in a disease like melanoma, which can be notoriously difficult to treat once it has disseminated to distant parts of the body. Early feedback from a ctDNA analysis could potentially offer a critical window for adjusting treatment strategies, initiating new therapies, or escalating surveillance, ultimately saving lives.
Building on Previous Successes: A Decade of ctDNA Research
The current study is not an isolated event but rather builds upon a growing body of research demonstrating the utility of ctDNA in cancer management. Previous investigations have shown ctDNA tests to be accurate in tracing the progression of other cancers, including colorectal and breast cancers. In 2021, the same research team published findings that linked higher ctDNA levels in patients with stage IV melanoma (where the cancer has spread throughout the body) to poorer survival rates. They also demonstrated that changes in ctDNA measurements during treatment could be used to stratify patients into those with better or worse prognoses.
The latest investigation, the largest to date assessing ctDNA as a predictor of recurrence in stage III melanoma, involved nearly 600 men and women who had previously participated in a clinical trial for this stage of the disease. The research team meticulously analyzed blood samples collected from participants across Europe, North America, and Australia, comparing ctDNA measurements against clinical evidence of cancer recurrence. Their sophisticated statistical analysis ensured that the predictions were robust, taking into account other factors that might influence recurrence, such as a patient’s sex, age, and the specific type of therapy received.
A Superior Predictive Tool?
One of the most compelling findings from the study is the comparative performance of ctDNA assessment. The results indicated that measuring ctDNA levels was as effective, and in some instances even better, at predicting recurrence than other experimental tests that examine the tumor itself. These comparison tests included those that measure immune activity within a group of cancer cells, highlighting the directness and sensitivity of the ctDNA approach.
"Unlike standard, tissue-based analyses of tumor cells, which can only suggest the likelihood of recurrence, circulating tumor DNA tests provide a clear, direct measure of the disease itself and can tell us outright that melanoma has returned," explained study senior author and dermatologist David Polsky, MD, PhD, the Alfred W. Kopf, M.D., Professor of Dermatologic Oncology in the Ronald O. Perelman Department of Dermatology at NYU Grossman School of Medicine. This distinction is critical: ctDNA offers a real-time snapshot of the disease’s presence and activity, rather than an indirect assessment of cellular behavior.
Addressing Limitations and Future Directions
Despite the significant promise of ctDNA testing, Dr. Polsky also offered a note of caution. He pointed out that in a small number of cases, cancer still recurred even when a patient had received a negative ctDNA test prior to starting therapy. This observation highlights the need for continuous improvement and refinement of the technology.
In response to this, the research team has outlined their next steps. They plan to focus on enhancing the sensitivity of their ctDNA test to capture even smaller amounts of tumor DNA, thereby potentially reducing the number of false negatives. Furthermore, they intend to conduct clinical trials to rigorously evaluate whether actively using ctDNA results to guide treatment decisions can demonstrably improve patients’ survival rates and overall quality of life. This move from prediction to guided intervention is a critical phase in translating research findings into tangible patient benefits.
The Broader Impact: Revolutionizing Melanoma Management
The implications of this research are far-reaching. If ctDNA testing becomes a routine part of melanoma care, it could lead to:
- Personalized Treatment Strategies: Oncologists can better tailor treatment plans based on an individual’s risk of recurrence, potentially sparing some patients from aggressive therapies while intensifying treatment for those at higher risk.
- Earlier Intervention: Detecting recurrence at its earliest stages allows for prompt intervention, which is often associated with better treatment outcomes and improved survival.
- More Efficient Clinical Trials: ctDNA can serve as a valuable biomarker in clinical trials, helping researchers to more rapidly assess the efficacy of new therapies and identify patient populations most likely to benefit.
- Reduced Healthcare Costs: By avoiding unnecessary treatments for low-risk patients and enabling earlier, more effective treatment for high-risk patients, ctDNA monitoring could potentially lead to more efficient allocation of healthcare resources.
The study was supported by funding from Novartis Pharmaceuticals Corporation. Dr. Polsky has reported advisory board membership and honoraria from various pharmaceutical companies and organizations, including Novartis and Merck, as well as research contracts and laboratory support from other entities. The terms of these relationships are being managed in accordance with NYU Langone Health’s policies.
Beyond Syeda and Polsky, the study involved a substantial international collaboration of researchers, including Jennifer Wiggins-Crosby and Saim Ali from NYU Langone Health; Georgina Long and Victoria Atkinson from Australia; James Garrett from Novartis Pharmaceuticals; Mario Santinami and Mario Mandala from Italy; Dirk Schadendorf and Axel Hauschild from Germany; Michael Millward from the University of Western Australia; Michael Smylie from Canada; Georgy Manikhas from Russia; Reinhard Dummer from Switzerland; Sachin Bajirao Adnaik from Novartis Healthcare Pvt. Ltd., India; and Monique Tan and Maya Dajee from Novartis Pharmaceuticals. This collaborative effort underscores the global significance and broad interest in advancing melanoma diagnostics and treatment.
In conclusion, the findings from NYU Langone Health offer a powerful testament to the potential of liquid biopsies, specifically ctDNA analysis, in revolutionizing the management of stage III melanoma. As this technology continues to evolve and be validated in larger clinical settings, it holds the promise of transforming how skin cancer recurrence is predicted and managed, ultimately leading to better outcomes for patients facing this challenging disease.
